Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $40 to $35.
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $40 to $35.